Send to:

Choose Destination
See comment in PubMed Commons below
Liver Int. 2014 Feb;34 Suppl 1:13-7. doi: 10.1111/liv.12399.

How to optimize current treatment of genotype 2 hepatitis C virus infection.

Author information

  • 1Liver Unit, Hospital Italiano, Buenos Aires, Argentina.


The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG-IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight-based RBV dosing approach has been considered satisfactory in patients with positive predictors of response. With the development of the direct antiviral agents (DAAs), shorter, better tolerated and more efficient treatments for HCV genotype 2 will become available, including interferon-free regimens. Until these new treatments are released, the decision to treat patients with HCV genotype 2 with currently approved drugs or to wait for future options must be made, taking into account the stage of fibrosis.

© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.


cirrhosis; direct antiviral agents; pegylated interferon; predictors of treatment response; ribavirin; treatment duration

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk